Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

Agios Pharmaceuticals (AGIO) stock falls as a late-stage trial for its lead drug mitapivat in sickle cell disease indicate a ...

Agios Pharmaceuticals plans to share data from RISE UP with the Food and Drug Administration to support the approval of the sickle cell disease indication.

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect ...

Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...

IGIB and the Serum Institute of India aims to make sickle cell treatment accessible to India's tribal communities, where the ...

Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...

A decade-long study by a Gurugram hospital has found success in curing Sickle Cell Disease among children through bone marrow (stem cell) transplantation, placing India among the leading nations in ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did ...

Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.

One of the most vital treatments for sickle cell patients is regular blood transfusions; sometimes, it's needed multiple times a year.